BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:09 PM
 | 
Sep 26, 2012
 |  BC Extra  |  Company News

Merck returning all vernakalant rights to Cardiome

Merck & Co. Inc. (NYSE:MRK) will return all rights to develop and commercialize IV and oral formulations of atrial fibrillation (AF) product vernakalant to partner Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME). On a conference call on Wednesday, Cardiome said Merck "made a business decision to elect to...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >